| アブストラクト | Background: Hepatotoxicity induced by atomoxetine (ATX) and methylphenidate (MPH) when used to treat ADHD is a rare but potentially serious complication. This study aims to describe the hepatic adverse drug reactions (ADRs) reported for ATX and MPH by analysing data from the EudraVigilance database. Methods: Individual case safety reports (ICSRs) listing ATX and/or MPH as suspected drugs and reporting at least one adverse event (AE) within the 'hepatobiliary disorders' system organ class (SOC) were extracted for the period from 1 January 2012 to 20 May 2025. Descriptive and disproportionality analyses were then performed. Results: During the study period, 421 ICSRs reporting AEs classified under the "hepatobiliary disorders" SOC and involving ATX and/or MPH as suspected drugs were retrieved (ATX, N = 232; MPH, N = 181). Most cases involved adult (N = 261) and female (N = 222) patients. The majority of reports were classified as serious (N = 349). Overall, 375 AEs were identified. Drug-induced liver injury (DILI) was the most frequently reported AE (N = 103 ATX; N = 47 MPH), followed by hepatitis (N = 20 ATX; N = 9 MPH) and jaundice (N = 15 ATX; N = 20 MPH). The disproportionality analysis, based on a head-to-head comparison, showed a higher reporting frequency of hepatobiliary disorders for ATX compared to MPH (ROR 2.41 [95%CI 2.11-3.11]). Specifically, ATX was associated with significantly higher reporting frequencies than MPH for the AEs of DILI, hepatitis, and jaundice (6.42 [4.45-9.06]; 6.48 [2.95-14.24]; and 2.19 [1.12-4.27], respectively). Conclusions: This analysis, based on the EudraVigilance database, suggests that both drugs are associated with hepatobiliary adverse drug reactions, with a higher overall reporting frequency observed for ATX. |
|---|
| ジャーナル名 | Pharmaceuticals (Basel, Switzerland) |
|---|
| Pubmed追加日 | 2026/7/28 |
|---|
| 投稿者 | Di Napoli, Raffaella; Laino, Ludovica Vittoria; Rafaniello, Concetta; Di Costanzo, Luigi; Sullo, Maria Giuseppa; Scavone, Cristina; Capuano, Annalisa |
|---|
| 組織名 | Department of Experimental Medicine, University of Campania "L. Vanvitelli",;80138 Naples, Italy.;Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, 80138;Naples, Italy.;Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Naples, Italy.;Department of Life Science, Health, and Health Professions, Link Campus;University, 00165 Roma, Italy. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42515803/ |
|---|
